# Ep. 188: Red flags of treatable rare myopathies Page: https://stenobird.com/podcast/eancast-weekly-neurology-5497158/ep-188-red-flags-of-treatable-rare-myopathies Text version: https://stenobird.com/podcast/eancast-weekly-neurology-5497158/ep-188-red-flags-of-treatable-rare-myopathies.md Podcast: [eanCast: Weekly Neurology](https://stenobird.com/podcast/eancast-weekly-neurology-5497158) Published: 2026-02-15T23:15:00+00:00 Episode link: https://eancast.podigee.io/188-neue-episode Audio file: https://audio.podigee-cdn.net/2353126-m-5e59e6ee3e0f953c61664ca6699c730a.mp3?source=feed Processing state: not_requested JSON: https://stenobird.com/v1/public/podcasts/eancast-weekly-neurology-5497158/episodes/ep-188-red-flags-of-treatable-rare-myopathies Duration seconds: 1973 ## Resource Moderator: Olimpia Musumeci (Messina, Italy) Guests: Antonio Toscano (Messina, Italy), Marianne De Visser (Amsterdam, Netherlands) In this episode, Olimpia Musumeci speaks with Antonio Toscano and Marianne de Visser about hereditary, particularly metabolic, and acquired myopathies, especially idiopathic inflammatory myopathies amenable to treatment. They review advances in pathophysiology, diagnostic approaches and novel therapies, highlighting clinical red flags and strategies that have a significant impact on timely diagnosis and management in daily neurological practice. ## Actions - request_transcript: `POST https://stenobird.com/v1/public/podcasts/eancast-weekly-neurology-5497158/episodes/ep-188-red-flags-of-treatable-rare-myopathies/transcription-requests` — Idempotently request low-priority transcript generation for this episode. - read_markdown: `GET https://stenobird.com/podcast/eancast-weekly-neurology-5497158/ep-188-red-flags-of-treatable-rare-myopathies.md` — Read the agent-friendly Markdown representation of this episode resource. A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed. ## Transcript Full transcripts are not published on public pages unless there is a clear rights basis.